{"id":"https://openalex.org/W4388907235","doi":"https://doi.org/10.1016/j.ejphar.2023.176202","title":"ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study","display_name":"ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study","publication_year":2023,"publication_date":"2023-11-22","ids":{"openalex":"https://openalex.org/W4388907235","doi":"https://doi.org/10.1016/j.ejphar.2023.176202","pmid":"https://pubmed.ncbi.nlm.nih.gov/37996010"},"language":"en","primary_location":{"id":"doi:10.1016/j.ejphar.2023.176202","doi":"https://doi.org/10.1016/j.ejphar.2023.176202","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejphar.2023.176202","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.ejphar.2023.176202","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074276825","display_name":"Natsuki Kubota-Ishida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Natsuki Kubota-Ishida","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. Electronic address: natsuki.ishida@meiji.com","R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan. Electronic address: natsuki.ishida@meiji.com","institution_ids":["https://openalex.org/I4405275510"]},{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025242435","display_name":"Chizuko Kaji","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Chizuko Kaji","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015128599","display_name":"Shogo Matsumoto","orcid":"https://orcid.org/0000-0001-8599-5868","observed_orcids":["https://orcid.org/0000-0001-8599-5868"]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shogo Matsumoto","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":"https://orcid.org/0000-0001-8599-5868","affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tsubasa Wakabayashi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tsubasa Wakabayashi","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067427016","display_name":"Takashi Matsuhira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takashi Matsuhira","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025026867","display_name":"Iori Okura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Iori Okura","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001185966","display_name":"Naoki Cho","orcid":"https://orcid.org/0000-0003-3544-7008","observed_orcids":["https://orcid.org/0000-0003-3544-7008"]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naoki Cho","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":"https://orcid.org/0000-0003-3544-7008","affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010711380","display_name":"Satoshi Isshiki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Satoshi Isshiki","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045633350","display_name":"Ko Kumura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ko Kumura","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089152746","display_name":"Yuji Tabata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405275510","display_name":"Meiji Seika Pharma Co., Ltd. (Japan)","ror":"https://ror.org/03qt4xn36","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405275510"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuji Tabata","raw_affiliation_strings":["R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"R&D Division, Meiji Seika Pharma Co., Ltd., 2-4-16, Kyobashi, Chuo-ku, Tokyo, 104-8002, Japan","institution_ids":["https://openalex.org/I4405275510"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5074276825"],"corresponding_institution_ids":["https://openalex.org/I4405275510"],"apc_list":{"value":2790,"currency":"USD","value_usd":2790},"apc_paid":{"value":2790,"currency":"USD","value_usd":2790},"fwci":0.6799,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.60088865,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"962","issue":null,"first_page":"176202","last_page":"176202"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12434","display_name":"Phosphodiesterase function and regulation","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12434","display_name":"Phosphodiesterase function and regulation","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/phosphodiesterase-4-inhibitors","display_name":"phosphodiesterase-4 inhibitors","score":0.9399999976158142},{"id":"https://openalex.org/keywords/anti-inflammatory-activity","display_name":"anti-inflammatory activity","score":0.7570000290870667},{"id":"https://openalex.org/keywords/apremilast","display_name":"apremilast","score":0.875},{"id":"https://openalex.org/keywords/brain-distribution","display_name":"brain distribution","score":0.6029999852180481},{"id":"https://openalex.org/keywords/vomiting","display_name":"vomiting","score":0.800000011920929},{"id":"https://openalex.org/keywords/cytokine-inhibition","display_name":"cytokine inhibition","score":0.6899999976158142},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.9139999747276306},{"id":"https://openalex.org/keywords/il-4","display_name":"IL-4","score":1.0},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.8389999866485596},{"id":"https://openalex.org/keywords/atopic-dermatitis","display_name":"atopic dermatitis","score":1.0},{"id":"https://openalex.org/keywords/oxazolone-induced-dermatitis","display_name":"oxazolone-induced dermatitis","score":0.8899999856948853},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.8920000195503235},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.5839999914169312},{"id":"https://openalex.org/keywords/safety-margin","display_name":"safety margin","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C62826618","wikidata":"https://www.wikidata.org/wiki/Q424304","display_name":"Phosphodiesterase","level":3,"score":0.635575532913208},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6248282194137573},{"id":"https://openalex.org/C2776766087","wikidata":"https://www.wikidata.org/wiki/Q418251","display_name":"Phosphodiesterase inhibitor","level":2,"score":0.5795656442642212},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45818203687667847},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.35836997628211975},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2592616677284241},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.125789076089859},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.11126059293746948}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000893","descriptor_name":"Anti-Inflammatory Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003876","descriptor_name":"Dermatitis, Atopic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005289","descriptor_name":"Ferrets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007249","descriptor_name":"Inflammation","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054703","descriptor_name":"Cyclic Nucleotide Phosphodiesterases, Type 4","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058988","descriptor_name":"Phosphodiesterase 4 Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D058988","descriptor_name":"Phosphodiesterase 4 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ejphar.2023.176202","doi":"https://doi.org/10.1016/j.ejphar.2023.176202","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejphar.2023.176202","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:37996010","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37996010","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.ejphar.2023.176202","doi":"https://doi.org/10.1016/j.ejphar.2023.176202","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ejphar.2023.176202","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322415","display_name":"Meiji Seika Pharma","ror":"https://ror.org/027tjex48"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W140715871","https://openalex.org/W156810961","https://openalex.org/W1604295258","https://openalex.org/W1919283206","https://openalex.org/W1955942895","https://openalex.org/W1979687697","https://openalex.org/W1982292637","https://openalex.org/W1988901842","https://openalex.org/W1989014719","https://openalex.org/W1994226794","https://openalex.org/W1996677952","https://openalex.org/W1998677128","https://openalex.org/W2002983787","https://openalex.org/W2029173044","https://openalex.org/W2056496442","https://openalex.org/W2083530312","https://openalex.org/W2099039357","https://openalex.org/W2106621815","https://openalex.org/W2119774957","https://openalex.org/W2123340622","https://openalex.org/W2166776515","https://openalex.org/W2545291810","https://openalex.org/W2595644139","https://openalex.org/W2610800468","https://openalex.org/W2781078917","https://openalex.org/W2781934223","https://openalex.org/W2883568898","https://openalex.org/W2897406695","https://openalex.org/W2902828135","https://openalex.org/W2928824653","https://openalex.org/W3045278545","https://openalex.org/W3081472252","https://openalex.org/W3138450947","https://openalex.org/W3167185496","https://openalex.org/W3180022284","https://openalex.org/W4235945692","https://openalex.org/W4256102116","https://openalex.org/W4280599153","https://openalex.org/W4281771694","https://openalex.org/W4318478086","https://openalex.org/W6791787499","https://openalex.org/W6838039154"],"related_works":["https://openalex.org/W4295261749","https://openalex.org/W4286110565","https://openalex.org/W2068947002","https://openalex.org/W7096507683","https://openalex.org/W1778153929","https://openalex.org/W1968343879","https://openalex.org/W2407353730","https://openalex.org/W7095142609","https://openalex.org/W1982292637","https://openalex.org/W2106621815"],"abstract_inverted_index":{"Phosphodiesterase":[0],"4":[1],"(PDE4)":[2],"inhibitors":[3,21],"are":[4],"expected":[5,210],"to":[6,13,33,164,211],"exhibit":[7],"efficacy":[8,137,182,215],"against":[9],"inflammatory":[10,196],"diseases":[11],"due":[12,32],"their":[14],"broad":[15],"pharmacological":[16],"activity.":[17],"The":[18,143,155],"launched":[19],"PDE4":[20],"apremilast,":[22],"crisaborole,":[23],"and":[24,38,50,72,87,102,111,121,153,183,201,216],"roflumilast":[25],"have":[26,177],"not":[27],"exhibited":[28],"sufficient":[29],"inhibitory":[30,173],"potential":[31],"poor":[34],"margins":[35,187],"of":[36,53,146,158,166,181,191,218],"effectiveness":[37,190],"tolerability.":[39,184],"In":[40,98],"this":[41],"report,":[42],"we":[43],"describe":[44],"the":[45,189,214],"non-clinical":[46],"efficacy,":[47],"brain":[48,144],"translocation,":[49],"vomit-inducing":[51],"effects":[52,90],"ME3183":[54,58,75,106,128,133,147,159,175,192],"compared":[55],"with":[56],"apremilast.":[57,142],"showed":[59,88,134],"extensive":[60],"cytokine":[61,120],"suppression":[62],"in":[63,81,91,100,103,135,151,168,193],"vitro":[64,101],"studies":[65],"using":[66],"human":[67],"peripheral":[68],"blood":[69],"mononuclear":[70],"cells":[71],"T":[73],"cells.":[74],"also":[76,107],"significantly":[77,108],"suppressed":[78,109],"skin":[79],"inflammation":[80],"a":[82,92,118,178],"chronic":[83],"oxazolone-induced":[84],"dermatitis":[85],"model":[86],"antipruritic":[89],"substance":[93],"P-induced":[94],"mouse":[95],"pruritus":[96],"model.":[97],"these":[99],"vivo":[104,136],"studies,":[105],"cytokines,":[110],"focusing":[112],"on":[113],"tumor":[114],"necrosis":[115],"factor-\u03b1":[116],"as":[117,123,199],"psoriasis-related":[119],"interleukin-4":[122],"an":[124],"atopic":[125,202],"dermatitis-related":[126],"cytokine,":[127],"potently":[129],"inhibited":[130],"both":[131],"cytokines.":[132],"at":[138],"lower":[139],"doses":[140],"than":[141],"distribution":[145],"was":[148,162],"sufficiently":[149],"low":[150],"mice":[152],"rats.":[154],"effective":[156],"dose":[157],"for":[160],"emesis":[161],"similar":[163],"that":[165],"apremilast":[167],"ferrets.":[169],"Given":[170],"its":[171],"high-potency":[172],"effects,":[174],"would":[176],"wide":[179,186],"margin":[180],"These":[185],"demonstrate":[188,213],"treating":[194],"many":[195],"diseases,":[197],"such":[198],"psoriasis":[200],"dermatitis.":[203],"An":[204],"on-going":[205],"phase":[206],"2":[207],"trial":[208],"is":[209],"further":[212],"safety":[217],"ME3183.":[219]},"counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-11-23T00:00:00"}